This study compared inspiratory characteristics of the Novolizer and Turbuhaler. Sixty patients with obstructive lung disease (40 asthmatics, 20 patients with COPD) and without DPI experience were enrolled into this investigator initiated, randomized, cross-over study. Collected data of 56 patients were eligible for analysis. Inspiratory pressure and inspiratory flow through both devices were measured in every patient using a double-beam oscilloscope. Peak inspiratory flow (PIF), duration of inspiratory flow > 60 l/min and increase in inspiratory pressure were significantly higher in the Novolizer group. In addition, the inspiratory flow rate 0.1 s after beginning of inhalation was over two-times higher at inhalation through the Novolizer compared to inhalation through the Turbuhaler. The Turbuhaler data, but not the Novolizer data, showed a significant negative correlation between lung function and inspiratory flow. The dynamic resistance of the Turbuhaler was 5.5-times higher than that of the Novolizer. Patients using the Turbuhaler had to invest a significantly higher inspiratory effort compared to the use of the Novolizer in order to achieve the same inspiratory flow (e.g., 60 l/min). Indeed, more than 40% of the patients in the Turbuhaler group failed to reach an inspiratory flow of 60 l/min. Overall, patients inhaling through the Novolizer had a better inhalation performance than those inhaling through the Turbuhaler.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.rmed.2004.02.003 | DOI Listing |
BMJ Open Respir Res
January 2025
Lane Fox Clinical Respiratory Physiology Research Unit, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Introduction: Patients recovering from severe acute exacerbations of chronic obstructive pulmonary disease (AECOPD) have a 30-day readmission rate of 20%. This study evaluated the feasibility of conducting a randomised controlled trial to evaluate clinical, patient-reported and physiological effects of home high-flow therapy (HFT) in addition to usual medical therapy, in eucapnic patients recovering from AECOPD to support the design of a phase 3 trial.
Methods: A mixed-methods feasibility randomised controlled trial (quantitative primacy, concurrently embedded qualitative evaluation) (ISRCTN15949009) recruiting consecutive non-obese patients hospitalised with AECOPD not requiring acute non-invasive ventilation.
Andes Pediatr
August 2024
Servicio de Neonatologia, Complejo Asistencial Dr. Sótero del Río, Santiago, Chile.
Sci Rep
January 2025
The Queen's Medical Center, 1301 Punchbowl Street, QET 4M, Honolulu, Hawai'i, 96813, USA.
High flow nasal cannula (HFNC) can reduce the need for intubation in patients with coronavirus disease-19 (COVID-19) pneumonia induced acute hypoxemic respiratory failure (AHRF), but predictors of HFNC success could be characterized better. C-reactive protein (CRP) and D-dimer are associated with COVID-19 severity and progression. However, no one has evaluated the use of serial CRP and D-dimer ratios to predict HFNC success.
View Article and Find Full Text PDFBMJ Open
January 2025
Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, PR China
Introduction: Preclinical studies have shown that oxygen therapy can improve ischaemic brain tissue oxygen tension, reduce reperfusion injury after revascularisation, promote neuroregeneration and inhibit inflammatory responses potentially exerting a beneficial effect after endovascular treatment (EVT) in patients with acute ischaemic stroke (AIS). However, the optimal fraction of inspired oxygen (FiO) during EVT under general anaesthesia is currently unknown. Therefore, we are conducting a randomised controlled trial (RCT) to evaluate the impact of high-concentration oxygen vs low-concentration normobaric oxygen on early neurological function after EVT.
View Article and Find Full Text PDFMonaldi Arch Chest Dis
December 2024
Department of Pulmonary Medicine, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry.
This cross-sectional study aimed to investigate the role of peak inspiratory flow rate (PIFR) in the management of inhalation therapy for patients with chronic obstructive pulmonary disease (COPD). Conducted in the Department of Pulmonary Medicine at a tertiary care institute from July 2021 to January 2022, this study included a total of 351 patients who were clinically diagnosed with stable COPD and currently receiving inhaler therapy. Participants underwent comprehensive assessments that included demographic data collection, the use of the ABCD assessment tool to evaluate disease severity, the COPD Assessment Test (CAT) for quality of life measurement, and assessments for adherence to inhaler therapy and inhaler technique proficiency.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!